Mum’s Journey Helps Rewrite Global Breast Cancer Treatment

Kylie Pardo was diagnosed with triple-negative breast cancer in 2017 at the age of 33. Her journey began when she discovered a lump in her breast, and was swiftly referred to Cabrini breast surgeon, Dr Jennifer Senior OAM.

The young mum was introduced to the possibility of participating in a clinical trial. Dr Senior referred Kylie to oncologist and cancer genetics specialist Associate Professor Yoland Antill, who led the Keynote 522 clinical trial at Cabrini.

The groundbreaking study has since changed the standard of care for women worldwide with stage 2 or 3 triple-negative breast cancer. As Professor Antill explains, “Keynote 522 is the addition of pembrolizumab, which is immune therapy, to chemotherapy for women with stage 2 or stage 3, who have high-risk, triple-negative breast cancer.”

The trial involved 1174 patients globally, and Kylie’s fit with the trial’s eligibility criteria saw her enthusiastically became one of these participants.

The trial represented a significant leap forward in breast cancer treatment.

A crucial aspect of Kylie’s story is her ability to have children post-treatment. Before starting chemotherapy, she underwent egg harvesting as a precautionary measure. However, three years after completing her cancer treatment, Kylie was able to conceive naturally. She gave birth to her third child, who is now 3.5 years old.

Reflecting on her experience, Kylie expresses pride and satisfaction in her participation, “I feel like I have made a difference along with everyone else who participated.” She highlights the importance of clinical research, “Science is there for a reason. And if you’re in the position to get on a trial and help yourself but help many other people, you have to have a go.”

Kylie’s case highlights the potential benefits of clinical trials in advancing cancer treatments. Her successful treatment and subsequent ability to expand her family serve as hope for other breast cancer patients.

Thank you to our generous Cabrini Foundation donors, whose invaluable support makes these life-changing trials possible. You truly make a difference, enabling Cabrini to advance medical research and improve patient care.

‍